Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Epinephrine for Metabisulfite Sensitivity Reactions
NCT06445374Phase 1Completed
- Start
- Jul 2024
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epinephrine in anaphylaxis. Primary endpoint: Time to resolution of systemic symptoms at 60 minutes. Started Jul 2024; status: completed.
02
Drugs
epinephrine
03
Conditions
anaphylaxis
Beyond the preview
Go deeper on NCT06445374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06445374.